Denis Yalkut, MD
Urology · Richmond, KYNPI 1700974797
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,513 of the $4,051 with a category attached, or 86.7%. It is spread thinly across 34 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 202 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$617
- Johnson & Johnson$524
- Sumitomo Pharma America, Inc.$513
- Urovant Sciences Inc$308
- Boston Scientific$253
- Axonics, Inc.$236
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,51387%
- Education$53913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 28 | $617 |
| Johnson & Johnson | 19 | $524 |
| Sumitomo Pharma America, Inc. | 33 | $513 |
| Urovant Sciences Inc | 25 | $308 |
| Boston Scientific | 9 | $253 |
| Axonics, Inc. | 7 | $236 |
| AbbVie(2 entities) | 8 | $164 |
| Merck | 6 | $121 |
| Pfizer | 7 | $113 |
| AstraZeneca | 7 | $112 |
| 180 Medical, Inc. | 4 | $83 |
| Tempus AI, Inc | 3 | $81 |
| Antares Pharma, Inc. | 4 | $80 |
| Myriad Genetic Laboratories, Inc. | 3 | $72 |
| Novartis | 4 | $72 |
| Laborie Medical Technologies Corp. | 1 | $70 |
| Bayer | 5 | $68 |
| Teleflex LLC | 3 | $60 |
| Olympus America Inc. | 2 | $51 |
| Coloplast | 3 | $50 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $50 |
| Convatec Inc. | 2 | $47 |
| Urogen Pharma, Inc. | 2 | $45 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Duchesnay USA Incorporated | 2 | $30 |
| Endo USA, Inc. | 1 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Bard Access Systems, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $18 |
| Vertex | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Accord Healthcare, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,051 in reported general payments places this provider in the 60th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 18 | $252,606 |
| GemtesaVibegron | 239 | $225,299 |
| MyrbetriqMirabegron | 47 | $37,460 |
| ElmironPentosan Polysulfate Sodium | 14 | $34,950 |
| Bethanechol Chloride | 177 | $19,762 |
| Dutasteride | 831 | $19,168 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 748 | $16,912 |
| Desmopressin Acetate | 86 | $16,716 |
| Estradiol | 254 | $12,661 |
| MovantikNaloxegol Oxalate | 13 | $10,984 |
| Tamsulosin Hcl | 695 | $10,278 |
| Methenamine Hippurate | 96 | $7,967 |
| Testosterone Cypionate | 104 | $7,257 |
| Ondansetron OdtOndansetron | 376 | $6,450 |
| Finasteride | 597 | $6,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $617 | $290,06665 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $513 | $225,299239 claims |
| PfizerPremarin | $113 | $5,64713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 139 urology providers in Kentucky.
Other urology in Richmond
- Thomas SlabaughLexington$102K
- Uzoma AneleLouisville$60K
- Lee EvansHopkinsville$56K
- Patrick HensleyLexington$50K
- Brooke EdwardsCrestview Hills$45K
- Robert LarkeCrestview Hills$22K
- Stephen MonnigLexington$18K
- Kellen ChoiLouisville$17K
- Rosa ParkLouisville$16K
- Brian ShayCrestview Hills$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.